Digital Health Roundup: BCI, Neuroethics, FDA Shifts, Wearables, And Megadeals
As brain-computer interfaces near US approval, neuroethics and neural data privacy move center stage. Major medtech deals reshape the market, while new FDA digital health leadership and updated AI, wellness and CDS guidances signal a more flexible regulatory approach.
Medtech Insight - February 27, 2026

Serious Injuries Linked To Abiomed Impella Heart Pump Component
The US FDA has issued an early alert concerning Abiomed’s Impella purge cassettes, a critical heart pump component that delivers rinsing fluid to the Impella catheter.
Medtech Insight - February 27, 2026

Growth Drivers: The Drugs Shaping Pharma’s Expansion In 2026
A deep dive into sales expectations for individual pharma products reveals incretin agonists, immunology biologics and new formulations of established blockbusters dominating growth forecasts this year, with Merck & Co., Lilly, AbbVie and Bristol Myers Squibb particularly well positioned in 2026.
Scrip - February 27, 2026

Generate’s $400m IPO Adds To Biotech Bounceback
The Flagship Pioneering company has completed the biggest initial public offering of 2026 so far, providing encouragement for more cash-hungry biotechs seeking a public listing.
Scrip - February 27, 2026

Zuellig Assumes Control Of Nicotinell In Korea
Through deal with Dr Reddy's, Singapore's Zuellig will commercialize Nicotinell NRT products in South Korea.
HBW Insight - February 27, 2026

Executives On The Move: Roche Gets A New Pharma Research Head
Recent moves in the industry include changes at the top at Artios Pharma, CNS Pharmaceuticals and GenSight Biologics, plus Daiichi Sankyo gets a new global R&D head.
Scrip - February 27, 2026

Boehringer Licenses Preclinical Immunology Program From UK’s Sitryx In $500m-Plus Deal
Boehringer Ingelheim has strengthened its immunology research pipeline by licensing Sitryx’s preclinical oral small molecule program targeting immune-driven diseases.
Scrip - February 27, 2026

Lessons On The Art Of Lobbying At AAM’s Access! 2026
During a candid and revealing discussion, lobbying experts shared trade secrets with the AAM’s Access! 2026 conference on how to get the generics and biosimilars industry’s message heard by lawmakers, as well as looking ahead to the importance of upcoming US midterms.
Generics Bulletin - February 27, 2026

‘Biology Is Dirty’: HHS’s Principal Deputy Counsel On How Biosimilar Firms Can Help US FDA
As FDA streamlines regulatory requirements for biosimilars, Robert Foster said during AAM’s annual meeting that if a company brings high-quality data to the agency, ‘sometimes the student ... teaches the tenured professor something new.’
Generics Bulletin - February 27, 2026

Beyond AI Pilots: India Pharma Chiefs Hone In, Watch The Manufacturing Space
India pharma leaders emphasize the need for AI integration beyond pilots, calling for an enterprise mindset to drive AI adoption and a focus on re-skilling for ‘everyone’. Discussions touched on AI’s role in driving manufacturing efficiencies and also India’s innovation trajectory.
Scrip - February 27, 2026

In Brief: Strong Results Advance DualityBio/BioNTech’s B7H3 ADC Into Phase III CRPC Trial
Clinical Data Readout: With a median follow-up of 6.5 months, updated findings from a Phase I/II study of DB-1311 (BNT324) in heavily pretreated mCRPC patients worldwide showed a median radiographic progression-free survival of 11.3 months and a median overall survival of 22.5 months.
Scrip - February 27, 2026

Elizabeth Arden Launches Flagship Scent, Calvin Kline Promotes Elixir Trio; Fragrance Roundup
Revlon’s Elizabeth Arden brand introduces its first flagship scent in eight years, while Calvin Klein names singer Rosalia as the face of its new scent trio that represents the highest scent concentration for the brand.
HBW Insight - February 27, 2026

Perrigo’s ‘Core’ Excludes Infant Formula Business
“Infant formula has consumed cash” and “at the end of the day, we need to be committed to improve our cash flow,” says CFO Eduardo Bezerra as Perrigo continues reviewing it options for the business.
HBW Insight - February 27, 2026

One Call Point, One Vision: Precision CEO Kurt Azarbazin’s Plan To Redefine Interventional Oncology
New Precision IO Group CEO Kurt Azarbarzin outlines the near-term strategy for Quantum Surgical’s robotic-assisted ablation platform and NeuWave Medical’s microwave technology. Quantum recently acquired NeuWave, but the companies will continue to operate independently.
Medtech Insight - February 27, 2026